Processing

Please wait...

Settings

Settings

Goto Application

1. JP2020141676 - COMPOSITIONS AND METHODS UTILIZING LYSOPHOSPHATIDYLCHOLINE SCAFFOLDS

Office
Japan
Application Number 2020072904
Application Date 15.04.2020
Publication Number 2020141676
Publication Date 10.09.2020
Publication Kind A
CPC
G01N 2500/10
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2500Screening for compounds of potential therapeutic value
10involving cells
A01K 67/0276
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
67Rearing or breeding animals, not otherwise provided for; New breeds of animals
027New breeds of vertebrates
0275Genetically modified vertebrates, e.g. transgenic
0276Knockout animals
A01K 2227/105
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
2227Animals characterised by species
10Mammal
105Murine
A01K 2267/03
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
2267Animals characterised by purpose
03Animal model, e.g. for test or diseases
A61K 49/0008
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
49Preparations for testing in vivo
0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
0008Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
A23L 33/10
AHUMAN NECESSITIES
23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A23B - A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT
33Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
10using additives
Applicants NATIONAL UNIV OF SINGAPORE
ナショナル ユニヴァーシティー オブ シンガポール
Inventors DAVID LAWRENCE SILVER
シルバー デビッド ローレンス
NGUYEN NAM LONG
グエン ナム ロング
ROBERT ZAHLER
ザーラー ロバート
Agents 清水 初志
春名 雅夫
山口 裕孝
刑部 俊
井上 隆一
佐藤 利光
新見 浩一
小林 智彦
大関 雅人
川本 和弥
Priority Data 61/882,693 26.09.2013 US
61/973,136 31.03.2014 US
61/992,822 13.05.2014 US
Title
(EN) COMPOSITIONS AND METHODS UTILIZING LYSOPHOSPHATIDYLCHOLINE SCAFFOLDS
(JA) リゾホスファチジルコリンの足場を利用する組成物及び方法
Abstract
(EN)

PROBLEM TO BE SOLVED: To provide a method of screening fatty acid formulations for parenteral nutrition and for live animal organ imaging.

SOLUTION: A method for screening one or more compounds to determine transport via the Mfsd2a protein, comprises: (a) contacting a biological mixture comprising the one or more compounds with a genetically modified mouse that comprises in its genome a homozygous disruption of the Mfsd2a gene (KO mouse) and a wild type mouse; (b) measuring the amount of the one or more compounds in a tissue or fluid of the KO mouse and the wild type mouse; and (c) comparing the amount of the one or more compounds in the tissue or fluid of the KO mouse and the wild-type mouse, where higher amounts of the one or more compounds in the wild-type mouse as compared with the KO mouse are an indication of transport of the compound via the Mfsd2a protein.

SELECTED DRAWING: Figure 17

COPYRIGHT: (C)2020,JPO&INPIT


(JA)

【課題】非経口栄養のための、及び生きている動物の臓器の画像化のための脂肪酸製剤のスクリーニング方法の提供。
【解決手段】Mfsd2aタンパク質を介した輸送を判定する化合物のスクリーニング方法であって、(a)そのゲノムにてMfsd2a遺伝子のホモ接合性の破壊を含む遺伝子操作されたマウス(KOマウス)及び野生型マウスに化合物を含む生物学的混合物を接触させることと、(b)KOマウス及び野生型マウスの組織または体液にて前記化合物の量を測定することと、(c)KOマウス及び野生型マウスの組織または体液にて前記化合物の量を比較することとを含み、KOマウスに比べて野生型マウスにおいて前記1以上の化合物の量がより多いことがMfsd2aタンパク質を介した前記化合物の輸送の指標である、スクリーニング方法。
【選択図】図17